All relevant data are within the paper and its Supporting Information files.

Background {#sec004}
==========

Patients with systemic lupus erythematosus (SLE) may have an increased risk of bone mineral density (BMD) loss and vertebral fractures (VF) according to cross-sectional studies \[[@pone.0196113.ref001]--[@pone.0196113.ref004]\]. Osteoporosis and fractures contribute to damage in the musculoskeletal system, which is frequently involved in patients with SLE \[[@pone.0196113.ref005]\].

BMD measurement by dual energy X-ray absorptiometry (DXA) is the gold standard to assess fracture risk in healthy men and women \[[@pone.0196113.ref006]\]. The utility of DXA in predicting fracture risk in SLE is unclear for two reasons. First, only small cross-sectional studies have reported on the use of DXA to discriminate the fracture status. Secondly, the relationship between low BMD and glucocorticoid therapy (GCT), which is extensively used for the treatment of SLE disease flares and complications, remains unclear \[[@pone.0196113.ref002],[@pone.0196113.ref004],[@pone.0196113.ref007],[@pone.0196113.ref008]\].

Identifying prevalent VF is important, since prevalent vertebral deformities are associated with a reduced quality of life \[[@pone.0196113.ref009]\], and increased mortality and risk of future fractures in the general population \[[@pone.0196113.ref010]\]. There are only a few studies on prevalent VF (using a standardized method of scoring vertebral deformities) and these showed at least one VF in 20--26.1% of SLE patients \[[@pone.0196113.ref002],[@pone.0196113.ref011],[@pone.0196113.ref012]\]. We recently showed that 20% of 110 SLE patients \[median follow-up 8 (IQR 8--9) years\] had radiographic VF at baseline and 32% had a new VF. The reported annual incidence rate of new morphometric VF is 3.5 (95% CI 2.4--4.91) per 100 patient/years \[[@pone.0196113.ref013]\]. A recent meta-analysis, including studies of VF prevalence and low BMD, reported an almost three-fold higher risk of VF in SLE patients (RR 2.97, 95% CI 1.71--5.16, *P* \< 0.001) compared with healthy controls \[[@pone.0196113.ref014]\]. Another recent systematic review without a meta-analysis also concluded that SLE patients are at risk of both reduced vitamin D plasma levels and low BMD \[[@pone.0196113.ref015]\].

Of patients with VF, 29--35.8% had normal BMD \[[@pone.0196113.ref011],[@pone.0196113.ref012]\], in line with results from studies in the general population reporting that the proportion of fractures attributable to osteoporosis is only 10--44%. This points to the limited value of BMD measurement in the assessment of future fracture risk. Moreover, these discrepancies between BMD and fracture risk may be because, in SLE, poor bone quality rather than decreased bone density plays the most important role in determining the risk of fractures, and VF occur at much high rates than expected on the basis of BMD, suggesting that the bone fragility of GCT users is not defined by the BMD. Indeed, cutoff values of BMD at the lumbar spine and femoral neck in women with VF treated with GCT were higher than those of controls \[[@pone.0196113.ref016]\].

Only one systematic meta-analysis has reported that SLE patients have significantly lower BMD levels than controls, and SLE is also significantly associated with increased fracture risk \[[@pone.0196113.ref014]\]. However, the relationship between BMD and GCT use and VF (using a standardized method of scoring vertebral deformities) has not been assessed in a meta-analysis or meta-regression. Therefore, we conducted a meta-analysis and meta-regression of studies evaluating: 1) BMD in SLE patients and controls, 2) BMD in SLE patients receiving GCT or not, and 3) BMD in SLE patients with or without VF.

Materials and methods {#sec005}
=====================

Search strategy {#sec006}
---------------

A systematic literature review was conducted using the following electronic databases: PubMed (1946-Week 2, January 2018), Cochrane library (1985-Week 2, Week 2, January 2018), EMBASE (1974-Week 2, January 2018), Virtual Health Library (VHL) (1998-Week 2, January 2018), and SciELO (1997-Week 2, January 2018), for published studies. We followed the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analysis, see [S1 File](#pone.0196113.s005){ref-type="supplementary-material"}) for meta-analysis of observational studies \[[@pone.0196113.ref017]\] in the data extraction, analysis, and reporting.

The following Medical Subject Heading (MeSH) terms were used: \"Lupus Erythematosus, Systemic,\" \"Osteoporosis,\" \"Bone Density,\" \"Densitometry" and \"Spinal Fractures\". Furthermore, we used 'text words' if there was no MeSH term, such as the cases of "SLE" abbreviation, "bone loss", "BMD" abbreviation, "dual energy X ray absorptiometry", "vertebral fractures" and "vertebral fragility". DeCS terms (Health Sciences Descriptors) were also used to find records and sources of information through controlled concepts in order to search the SciElo and VHL databases. Studies were limited to those carried out in adult humans and published in English. References from the articles deemed relevant were hand-searched.

Study selection and eligibility criteria {#sec007}
----------------------------------------

Prospective longitudinal and cross-sectional studies in SLE patients (regardless of menopausal status) were considered for review. Studies that used accepted and validated classification criteria for SLE were included. Case reports, conference abstracts, letters to editors, and studies not reporting the prevalence of osteoporosis or low BMD or VF prevalence were excluded. Papers were included if BMD was evaluated by dual-energy X-ray absorptiometry (DXA) at any of the total hip, femoral neck and lumbar spine. We included studies where VF was identified by standardized vertebral morphometry. In addition, the reference lists of relevant reviews and articles were manually retrieved to find other possible studies.

When various reports from the same study were published, only the most recent or informative one was included. However, if more than one publication described a single study but each presented new and complementary data, both were included and analyzed in separate analyses.

We first reviewed the titles and abstracts of studies found in the literature search and decided whether they conformed to the following research topics: 1) mean difference in BMD levels between SLE patients and controls, 2) mean difference in BMD levels between women and men with SLE, 3) mean BMD differences in patients with and without GCT, and 4) mean BMD differences in SLE patients with and without VF. Articles selected were evaluated by two investigators independently using the same selection criteria. The two resulting databases were compared and disagreements resolved by consensus.

Data extraction {#sec008}
---------------

The following data were extracted from studies included: first author, publication year, study design, population studied, number of participants, number of cases and controls, mean age, ethnicity, use of GCT, cumulative GCT dose, BMD measurement sites and VF assessment method. Definitions of GCT therapy were taken from the articles included ([S2 Table](#pone.0196113.s007){ref-type="supplementary-material"}).

We were able to extract several effect sizes from a single study. For example, some studies reported mean BMD for cases and controls, disaggregated by region and gender. The nested nature of the data is taken into account in the multilevel linear (mixed-effects) model (see statistical methods).

Assessment of methodological quality {#sec009}
------------------------------------

The Oxford Centre for Evidence-Based Medicine (EBM): 2011 Levels of Evidence criteria were used to assess the strength of the evidence for all studied included studies \[[@pone.0196113.ref018]\]. Clinical evidence was divided into 5 levels ranging from I to V as follows (diagnosis question): Level 1 Systematic review of cross-sectional studies with consistently applied reference standard and blinding; Level 2 Individual cross-sectional studies with consistently applied reference standard and blinding; Level 3 Non-consecutive studies, or studies without consistently applied reference standards; Level 4 Case-control studies, or "poor or non-independent reference standard; Level 5 Mechanism-based reasoning. Any disagreement was resolved through discussion and consensus of investigators.

Statistical methods {#sec010}
===================

Due to the diversity of studies found, three meta-regression analyses were made: The first aimed to assess possible differences in BMD between SLE cases and controls. The second analyzed the effect of treatment (GCT) on BMD in SLE cases and the third evaluated differences in BMD between SLE cases with and without VF.

We were able to extract more than one effect measure from a single study; therefore, we fit a multilevel linear (mixed-effects) model \[[@pone.0196113.ref019]\] to the three scenarios. The first hierarchical level corresponds to a single effect measure, and in the second level several effect measures are reported.

The following strategy was employed in order to obtain a final, most parsimonious model in each case: first, the variance component structure was obtained by fitting several models with a saturated fixed-effects structure (all relevant covariates plus full interactions) and different variance models (fixed effects, mixed effects and multilevel mixed-effects). The most parsimonious variance structure was chosen according to the basis likelihood ratio test and AIC criteria. Once the variance structure was determined, the mean structure was assessed, subtracting interactions and covariates and, again, the most parsimonious mean structure was chosen on the basis likelihood ratio test and AIC criteria. Heterogeneity was calculated using Higgins's (I2) tests. The I2 test showed the proportion of observed dispersion that was real rather than spurious and was expressed as a ratio ranging from 0% to 100%. I2 values of 25%, 50%, and 75% were qualitatively classified as low, moderate, and high respectively.

Using the selected models, the rank correlation test for funnel plot asymmetry was assessed to check for publication bias. The analysis was performed with the R 3.3.2 metaphor package \[[@pone.0196113.ref020]\].

Results {#sec011}
=======

Identification of relevant studies {#sec012}
----------------------------------

[Fig 1](#pone.0196113.g001){ref-type="fig"} shows a flow diagram of how relevant studies were identified. A total of 12875 articles were identified through the PubMed database search and an additional 3050 articles were retrieved through other sources (additional databases and hand search of relevant bibliographies). After duplicates were removed there were 2185 potentially-relevant articles. In all, 2103 studies were excluded during the initial screening through review of titles and abstracts in addition to 14 foreign language studies. The full texts of the remaining 68 studies were thoroughly reviewed. Of these, 26 were excluded due to: randomized clinical trials (n = 7), incomplete data (n = 3), T-score report but not BMD (n = 4), overlapping reports from the same research group (n = 16). The remaining 38 studies were included in the final analysis. See supporting information file showing detailed search criteria for PubMed-MeSH database ([S1 Table](#pone.0196113.s006){ref-type="supplementary-material"}).

![Flow diagram detailing the literature search.](pone.0196113.g001){#pone.0196113.g001}

Characteristics of studies included in the final analysis {#sec013}
---------------------------------------------------------

The 38 studies included were published between 1990 and 2017: 7 came from China \[[@pone.0196113.ref011],[@pone.0196113.ref021]--[@pone.0196113.ref026]\], 3 from Brazil \[[@pone.0196113.ref027]--[@pone.0196113.ref029]\], 3 from Spain \[[@pone.0196113.ref030]--[@pone.0196113.ref033]\], 2 from the United States \[[@pone.0196113.ref007],[@pone.0196113.ref034]\], 2 from Germany \[[@pone.0196113.ref035],[@pone.0196113.ref036]\], 2 from Hungary \[[@pone.0196113.ref037],[@pone.0196113.ref038]\], 2 from Mexico \[[@pone.0196113.ref008],[@pone.0196113.ref012]\], 2 from Italy \[[@pone.0196113.ref001]\], 2 from Sweden \[[@pone.0196113.ref004],[@pone.0196113.ref039]\] and 1 each from the United Kingdom \[[@pone.0196113.ref040]\], South Africa \[[@pone.0196113.ref041]\], Australia \[[@pone.0196113.ref003]\], Denmark \[[@pone.0196113.ref042]\], Italy \[[@pone.0196113.ref001],[@pone.0196113.ref043]\], Belgium \[[@pone.0196113.ref044]\], Norway \[[@pone.0196113.ref045]\], Austria \[[@pone.0196113.ref046]\], Bulgaria \[[@pone.0196113.ref047]\], Thailand \[[@pone.0196113.ref048]\], Singapore \[[@pone.0196113.ref049]\], The Netherlands \[[@pone.0196113.ref050]\] and Japan \[[@pone.0196113.ref051]\]. In total 3442 SLE cases and 6198 controls were included in the analysis of BMD (9232 women and 408 men). Eleven studies were suitable for BMD comparison in SLE patients receiving GCT (n = 358) or not (n = 354).

The study characteristics are described in [Table 1](#pone.0196113.t001){ref-type="table"} including the Oxford Centre for EBM 2011 Levels of Evidence. The most frequent level of evidence was level IV in 25 studies, followed by 8 and 3 studies corresponding to level II and III of evidence, respectively. The characteristics of studies evaluating VF are shown in [Table 2](#pone.0196113.t002){ref-type="table"}. Only 5 articles evaluated VF using a standardized method, making it possible to compare BMD between SLE patients with and (n = 189) and without VF (n = 506).

10.1371/journal.pone.0196113.t001

###### Characteristics of studies included comparing SLE cases and controls.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Setting\          Ethnicity          SLE participants   Controls     Menstrual status in SLE   GCT use in SLE (%)   GCT dose   Level of evidence                                                                                                                     
  ----------------------- ----------------- ------------------ ------------------ ------------ ------------------------- -------------------- ---------- ------------------- ------ ---- ----- ----- ------ ---------------------------------------------------------------------------------- -----
  Dhillon 1990            UK                NR                 22                 NR           22                        0                    14         NR                  14     0    22    0     54.5   At least 10 mg/d for at least 6 months                                             IV

  Kalla 1993              South Africa      NR                 46                 31           46                        0                    108        NR                  108    0    46    0     47.8   NR                                                                                 IV

  Formiga 1995            Spain             Caucasian          74                 30           74                        0                    50         NR                  50     0    74    0     \-     Mean cumulative dose: 32.5 (range 2.7--116.4) g                                    III

  Pons 1995               Spain             Caucasian          43                 NR           43                        0                    43         NR                  43     0    43    0     65.1   Cumulative range dose: 2.4--68.7 g                                                 IV

  Formiga 1996            Spain             Caucasian          20                 37           0                         20                   40         39                  0      40   NR    NR    \-     Cumulative dose 17.6 (range 8--60) g                                               IV

  Chen 1996               China             Asian              56                 31           56                        0                    15         29                  15     0    56    0     98.2   Mean 10 mg/d                                                                       IV

  Kipen 1997              Australia         NR                 97                 44           97                        0                    0          \-                  \-     \-   60    37    71     Median 11.6 (0.5--85.6) mg/d                                                       IV

  Hansen 1998             Denmark           NR                 36                 39           35                        1                    0          \-                  \-     \-   20    11    NR     Cumulative dose: 12.5 (3.0--22. 9) g                                               IV

  Sinigaglia 1999         Italy             NR                 84                 30           84                        0                    145        NR                  145    0    84    0     100    Cumulative dose 23.1 (0.2-127-0) g                                                 

  Teichman 1999           Germany           NR                 55                 58           55                        0                    20         54                  20     0    33    22    63.6   NR                                                                                 IV

  Jardinet 2000           Belgium           NR                 35                 30           35                        0                    0          \-                  \-     \-   35    0     82.8   Cumulative dose 15.8 ± 14.9 g                                                      IV

  Gilboe 2000             Norway            100% Caucasian     75                 45           66                        9                    150        NR                  132    18   38    28    85     Cumulative dose 21.8 (0.23--113.4) g                                               IV

  Redlich 2000            Austria           NR                 30                 33           30                        0                    39         NR                  39     0    30    0     67     Cumulative dose 14.6 (3.5) g                                                       IV

  Becker 2001             Germany           NR                 64                 33           33                        31                   0          \-                  \-     \-   62    2     87.5   2.5--100 mg PDN/day                                                                IV

  Bhattoa 2001            Hungary           NR                 23                 46           0                         23                   40         48                  0      40   \-    \-    91.3   Cumulative dose 33.4 (0--144.1) g                                                  IV

  Lakshminarayanan 2001   US                Caucasian          92                 33           92                        0                    0          \-                  \-     \-   44    48    97.8   Cumulative dose 31.6 (0.5--194.9) g                                                IV

  Bhattoa 2002            Hungary                              79                 49           79                        0                    0          \-                  \-     \-   30    49    89.7   Cumulative dose 13.8 (0--94.7) g                                                   IV

  Boyanov 2003            Bulgaria          NR                 48                 NR           48                        0                    0          \-                  \-     \-   35    13    66.6   Cumulative dose 34.4 (9--90) g                                                     IV

  Uaratanawong 2003       Thailand          Asian              118                NR           118                       0                    0          \-                  \-     \-   118   0     62.7   Cumulative dose 5.2 (0.14--27.0) g                                                 IV

  Coimbra 2003            Brazil            Mixed              60                 33           60                        0                    64         31                  64     0    60    0     98.3   Cumulative dose 29.7 (1.2--76.7) g                                                 III

  Borba 2005              Brazil            Mixed              70                 32           70                        0                    20         32                  20     0    70    0     NR     With VF 15.3± 12.7 mg/day and without VF 15.7±13.1 mg/d                            II

  Mok 2008                China             Asian              40                 43           0                         40                   40         43                  0      40   .     \-    85     \-                                                                                 II

  Li 2009                 China             Asian              152                48           152                       0                    0          \-                  \-     \-   48    104   91.4   Median dose 6.4 (4.7--8.4) mg/d                                                    II

  Mendoza-Pinto 2009      México            Mixed              210                43           210                       0                    0          \-                  \-     \-   106   104   \-     Mean cumulative dose 18.7 ± 19.5 g/d                                               II

  Almehed 2010            Sweden            Caucasian          150                40           150                       0                    0          \-                  \-     \-   67    81    86     Cumulative dose 11 (0.1 to 97.5)                                                   III

  Alele 2011              US                Cauca              153                White: 45\   153                       0                    4920       White: 53\          4920   0    92    61    NR     NR                                                                                 II
                                                                                  Black: 42                                                              Black: 43                                                                                                                             

  Mok 2012                China             Asian              353                42           331                       22                   0          \-                  \-     \-   226   127   81     Mean 4.6 ± 4.4 mg/d                                                                II

  Tang 2013               China             Asian              180                42           180                       0                    180        43                  180    0    110   70    100    Cumulative 18.6 (10.6--27.8) g                                                     II

  Mak 2013                Singapore         Asian              45                 50           37                        8                    45         49                  37     8    13    24    NR     Cumulative dose10.00 ± 10.7 g                                                      IV

  Jacobs 2013             The Netherlands   72.2% Caucasians   126                39           113                       13                   0          \-                  \-     \-   103   23    51.6   Mean 9.2±10.8 mg/d                                                                 IV

  Furukawa 2013           Japan             Asian              52                 NR           52                        0                    0          \-                  \-     \-   33    19    92.3   Mean daily dose: 8.4 mg                                                            IIb

  Bonfá 2015              Brazil            NR                 211                33           211                       0                    154        32                  154    0    211   0     75.4   Cumulative dose: 28.6±22.1 g                                                       IV

  Ajeganova 2015          Sweden            NR                 111                49           99                        12                   111        49                  99     12   63    48    60.4   Median dose 5.0 (3.7--10.0) mg/d                                                   IV

  Sun 2015                China             Asian              119                33           119                       0                    0          \-                  \-     \-   105   14    0      0                                                                                  IV

  Salman-Monte            Spain             Caucasian          67                 53           67                        0                    0          \-                  \-     \-   29    38    80.5   NR                                                                                 IV

  Carli 2016              Italy             Caucasian          186                46           175                       11                   0          \-                  \-     \-   128   58    NR     Mean cumulative dose in patients with OP 37.1 ± 25.5 g; without OP 24.4 ± 16.6 g   IV

  Guo 2017                China             Asian              60                 26           0                         60                   0          \-                  \-     \-   \-    \-    0      0                                                                                  IV
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: GCT = glucocorticoid therapy; d = day; g = grams; mg = milligrams; OP = osteoporosis; PDN = prednisone; NR = Not reported; UK = United Kingdom; US = United States; VF = vertebral fracture

\* = mean.

10.1371/journal.pone.0196113.t002

###### Characteristics of included studies comparing SLE with and without vertebral fractures.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Setting\     Ethnicity   SLE patients with vertebral fractures   SLE patients without vertebral fractures   Menstrual status in SLE   GCT dose                                                                                                       
  ------------------------ ------------ ----------- --------------------------------------- ------------------------------------------ ------------------------- ---------- --------- -------- --------- ------- --------- --------- ------------------------------------------ ------------------------------------------
  **Borba 2005**           **Brazil**   **Mixed**   **15**                                  **28**                                     **15**                    **0**      **55**    **32**   **55**    **0**   **NR**    **NR**    **15.3± 12.7 mg/day**                      **15.7±13.1 mg/day**

  **Mendoza-Pinto 2009**   **México**   **Mixed**   **53**                                  **50**                                     **53**                    **0**      **157**   **41**   **157**   **-**   **106**   **104**   **Mean cumulative dose 25.3 ± 26 g/day**   **Mean cumulative dose 17.2±18.2 g/day**

  **Li 2009**              **China**    **Asian**   **31**                                  **55**                                     **31**                    **0**      **121**   **46**   **121**   **-**   **48**    **104**   **Median dose 5.0 (3.1, 8.4) mg/day**      **Median dose**\
                                                                                                                                                                                                                                                                                **6.4 (4.8, 8.2)**

  **Furukawa 2013**        **Japan**    **Asian**   **26**                                  **40**                                     **26**                    **0**      **26**    **50**   **26**    **-**   **33**    **19**    **7.9 ± 4.5 mg/day**                       **8.9 ±5.2 mg/day**

  **Bonfá 2015**           **Brazil**   **NR**      **64**                                  **36**                                     **64**                    **0**      **147**   **32**   **147**   **0**   **211**   **0**     **Cumulative dose**\                       **Cumulative dose**\
                                                                                                                                                                                                                                     **28.8±20.8 g**                            **28.5±22.7 g**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GCT = glucocorticoid therapy; g = grams; mg = milligrams; VF = vertebral fracture

\* = mean

NR = Not reported

Results of meta-regressions {#sec014}
---------------------------

In the three groups analyzed, we found that the best variance structure was a two level model with random effects at the level of single effect measures and another random effect at the level of studies. In addition, we assessed the need for adjustment by gender and found no significant effect for this variable in any group. The only covariate that needed adjustment was the region of the measure, which appears systematically in the three final models. [Table 3](#pone.0196113.t003){ref-type="table"} shows the most relevant results from this analysis. High heterogeneity (see I2 in [Table 3](#pone.0196113.t003){ref-type="table"}) between studies was observed.

10.1371/journal.pone.0196113.t003

###### Results of the most parsimonious models for the groups of studies.
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  Group                 Mean structure   estimate   se        ci.lb     ci.ub      Pval        
  --------------------- ---------------- ---------- --------- --------- ---------- ---------- ----
  Case-Controls         intrcpt          1.0023     0.0129    0.9771    1.0275     \< .0001   I2
  Region2               -0.1842          0.0065     -0.197    -0.1714   \< .0001   97.5054    
  Region6               -0.1052          0.0074     -0.1196   -0.0907   \< .0001   R2         
  Individual type CTR   0.0566           0.0069     0.0431    0.0701    \< .0001   0.5229     
  GTC treatment         intrcpt          0.9924     0.032     0.9297    1.055      \< .0001   I2
  Region2               -0.1475          0.0214     -0.1893   -0.1056   \< .0001   96.8124    
  Region6               -0.0855          0.0295     -0.1434   -0.0276   0.0038     R2         
  treatment-            0.0259           0.0196     -0.0124   0.0643    0.1855     0.2623     
  Vertebral fractures   intrcpt          0.9204     0.0357    0.8504    0.9904     \< .0001   I2
  Region2               -0.1592          0.0203     -0.1989   -0.1194   \< .0001   95.7399    
  Region6               -0.0777          0.0152     -0.1075   -0.0479   \< .0001   R2         
  FV-                   0.0331           0.0137     0.0063    0.06      0.0156     0.2621     

Reference categories for Region, case-control status, treatment status and vertebral fractures status are Region 1, Case, GCT treatment + and FV + respectively. Region1: Lumbar, Region 2: Femoral, Region 6: total hip. Individual type Case: cases, Individual type CTR: controls. GCT treatment+: group under treatment; GCT treatment-: group without treatment. FV+: group with fractures; FV: group without fractures. I2: Heterogeneity by means of Higgins's tests

Abbreviation: GCT: glucocorticoid; ci.lb: confidence interval lower bound; ci.ub: confidence interval upper bound

Evidence of significant publication bias was identified by means of the rank correlation test for funnel plot in the case-control analysis group (p-value = 0.0446), but was not observed in the other two groups ([S1 Fig](#pone.0196113.s001){ref-type="supplementary-material"}.).

Comparison between SLE patients and controls {#sec015}
--------------------------------------------

We identified 8986 participants (2899 patients with SLE vs. 6087 controls) in the analysis of BMD. There were significant differences in mean BMD between cases and controls, with controls having a higher BMD (mean difference cases/controls: -0.0566 95% CI (-0.071, -0.0439; p = \< 0.0001). [S2 Fig](#pone.0196113.s002){ref-type="supplementary-material"} shows the forest plot corresponding to this meta-regression.

Comparison of BMD between SLE patients with (n = 348) and without (n = 169) GCT therapy showed no significant differences in BMD ([S3 Fig](#pone.0196113.s003){ref-type="supplementary-material"}) between treated and non-treated SLE patients (p-value: 0.1303).

Comparison of BMD between SLE patients with and without VF 694 SLE patients were included in the analysis of VF (189 with VF vs. 505 without VF) ([Table 2](#pone.0196113.t002){ref-type="table"}). Patients with VF had a lower BMD than those without (mean difference without FV--with FV: 0.033; 95%CI: (0,006--0.06); p-value: 0.0156). [S4 Fig](#pone.0196113.s004){ref-type="supplementary-material"} shows the forest plot corresponding to this analysis.

Discussion {#sec016}
==========

This study provides insights into the inconsistently reported relationship between SLE and BMD through a meta-analysis implementing a meta-regression tool. As suggested by the majority of studies reviewed studies our meta-analysis concluded that, overall, individuals with SLE have a lower BMD than non-SLE controls. Similarly, a recent meta-analysis showed that SLE patients had significantly lower BMD levels than controls in the whole body, femoral neck, lumbar spine and total hip \[[@pone.0196113.ref014]\]. The strength of this meta-analysis using a meta-regression lies in evaluating the anatomical regions of BMD measure as a whole, acting as covariates in the regression, without the need for subgroup analyses that might have a greater bias as the previous meta-analysis did \[[@pone.0196113.ref014]\].

No gender-specific differences were found between SLE cases and controls, even though low BMD is a gender-related condition. Both female and male SLE patients had a lower BMD at any region (lumbar spine, total hip and femoral neck) than healthy controls. To date, no gender-specific differences have been reported in these pathogenic mechanisms, although an already-fragile bone, such as that observed in postmenopausal women due to hormonal loss, may play a role in accelerating bone structure disruption \[[@pone.0196113.ref052]\]. Most studies included involved a higher number of premenopausal (n = 1913) than postmenopausal women (n = 823), which could be a reason for the lack of impact of gender on BMD.

We found no significant differences in the effect of GCT therapy on BMD at different regions between SLE patients with and without GCT. GCT are widely used to treat SLE disease flares and complications and might have beneficial effects by reducing the adverse effects of systemic inflammation on bone. The beneficial effects produced by suppressing the impact of inflammation on bone turnover might outweigh the harmful effects of GCT. Cross-sectional studies on the relationship between glucocorticoid use and BMD in SLE show conflicting results \[[@pone.0196113.ref053]\]. There is a wide disparity in the GCT doses, range, mean and cumulative dose and time of exposure in the studies evaluated that could partly explain the lack of between-group differences and result in probable bias \[[@pone.0196113.ref054]\].

The pathophysiologic mechanisms of impaired bone quality in GCT users remain unclear. Bone quality is determined by architecture, turnover, microdamage accumulation, mineralization and bone matrix protein such as collagen. In vivo studies have shown that GCT administration causes low bone turnover due to the suppression of osteoblast function, the induction of apoptosis in osteoblasts \[[@pone.0196113.ref055]\], and a major loss of trabecular connectivity \[[@pone.0196113.ref056]\]. GCT also affect bone geometry by reducing bone formation in periosteal surfaces \[[@pone.0196113.ref057]\]. This suggests that GCT administration leads to deterioration in bone structure. Since very few studies have assessed the trabecular microstructure either by computed tomography (CT) or magnetic resonance techniques in SLE \[[@pone.0196113.ref058]--[@pone.0196113.ref061]\], these studies were not included in our meta-analysis.

VF are the most common type of osteoporotic fracture and are associated with substantial morbidity and decreased survival. They are diagnosed using the Genant semi-quantitative method, which requires a ≥20% decrease in vertebral height (anterior, mid or posterior dimensions), estimated visually, to diagnose a vertebral fracture. A recent meta-analysis including two studies \[[@pone.0196113.ref062],[@pone.0196113.ref063]\] reported an almost three-fold higher risk of VF in SLE patients (RR 2.97, 95% CI 1.71--5.16, P \< 0.001) compared with healthy controls \[[@pone.0196113.ref014]\]. However, in the studies included, VF were not assessed using a standardized method such as the Genant semi-quantitative method and, in addition, the impact of BMD measurements was not evaluated. In our meta-analysis, including more studies (five)\[[@pone.0196113.ref011],[@pone.0196113.ref012],[@pone.0196113.ref028],[@pone.0196113.ref029],[@pone.0196113.ref051]\] using a standardized method for VF detection, SLE patients with VF had lower BMD measurements either at the lumbar spine, total hip or femoral neck, compared to patients without VF, even though VF in GCT-induced osteoporosis may occur at higher BMD measurements than those associated with postmenopausal osteoporosis, according to a large study \[[@pone.0196113.ref064]\]. As mentioned, we found no significant effect for gender in any group, including VF. We were not able to evaluate the direct impact of GCT use on the VF risk, because not all studies included measured this relationship and also because differences in reporting steroid use limited the ability to extract this information.

Meta-regression is a tool used in meta-analysis to examine the impact of moderator variables on study effect sizes using regression-based techniques. This type of approach was different than that used by a previous meta-analysis \[[@pone.0196113.ref014]\] which used subgroup analyses techniques. Meta-regression is more effective at this task than standard meta-analytic techniques \[[@pone.0196113.ref065]\].

Our study has several limitations and the results should be interpreted with caution. First, the review is preliminary, partly due to the scarcity of reports, making definitive conclusions difficult. We included only studies in adults and did not include children or adolescents because bone density differs considerably between them. Secondly, there was high heterogeneity (see [Table 3](#pone.0196113.t003){ref-type="table"}) between studies. A meta-analysis using individual patient data is recommended to provide good evidence for bone loss and fracture risk in SLE patients. Additionally, there were variations in the definition of GCT therapy between studies. Several methods were identified to define the risk of low BMD due to GCT treatment in SLE patients. However, we used "current use" or "ever use" binary response definitions to compare SLE patients with or without GCT therapy. The "current use" definition examines the association between BMD or fracture and whether the patient was exposed to GCT on the day of the measurements: important assumptions for this definition are that any prior GCT exposure does not affect the risk of low BMD or fracture, and the dose of GCT on the day of the measurements is not important. The "ever use" definition, conversely, assumes that all historical therapy affects the risk of fracture, but is regardless of how recently the therapy was taken. Thirdly, several covariates of clinical importance were not included in our analysis, such as ethnicity and post-menopausal status when comparing SLE patients and controls. Fourthly, we were not able to calculate odd ratios or relative risk for VF in SLE patients, since most studies in this subgroup analysis did not include healthy controls. Fifthly, most studies included had cross-sectional designs with a small sample size; there is no doubt that large prospective cohort studies adjusting for cofounders are more appropriate in assessing the fracture risk in SLE patients, in order to establish a real temporal cause-effect relationship. In fact, our review has disclosed the scarcity of longitudinal studies on this topic. We believe this meta-regression should encourage the research community to initiate and design future cohort studies.

Finally, significant publication bias was found for the first analysis (comparison of SLE patients and controls). However, this may probably be due to the small study effect rather than true publication bias, especially in the presence of significant heterogeneity between studies \[[@pone.0196113.ref066]\]. The majority of meta-analyses are based on a series of studies to produce a point estimate of an effect and measures of the precision of that estimate. In addition, a meta-regression model seeks to determine whether a study-level covariate is a plausible source of heterogeneity in a set of treatments or an output variable effect. Upon doing such analyses, as we have shown in the present study, the bias of the small study sample size of the independent studies is overcome. As studies become less precise, such as in smaller trials, the results of the studies can be expected to be more variable than the more precise larger studies; this aspect was cancelled out in the present study through the publication bias analyses and, as a result, allowed an objective assessment\[[@pone.0196113.ref067],[@pone.0196113.ref068]\].

In conclusion, this meta-analysis, using meta-regression analytic techniques, showed that SLE patients have lower BMD levels than healthy controls independently of the skeletal site of measurement and gender. In addition, BMD levels at any region did not differ between SLE patients with and without GCT therapy. SLE patients with VF have lower BMD levels than those without. Larger prospective cohort studies are needed to provide a more accurate assessment of the relationship between SLE and fracture risk. Future studies evaluating effective osteoporosis screening and prevention in SLE patients are also required.
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###### Funnel plots for the three models supplementary.

A. Funnel plot of the model for case-controls. B. Funnel plot for GCT therapy. C. Funnel plot for vertebral fractures.
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###### Forest plot for case- control study.

Regions codified are as follows: 1) lumbar spine 2) femoral neck and 3) total hip.
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###### Forest plot for therapy effect study.

Regions codified are as follows: 1) lumbar spine 2) femoral neck and 3) total hip.
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###### Forest plot for vertebral fractures study.

Regions codified are as follows: 1) lumbar spine 2) femoral neck and 3) total hip.
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###### Glucocorticoid use definitions for the analysis comparing patients with and without GCT therapy.
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